Natera Inc
NASDAQ:NTRA
Natera Inc
NASDAQ:NTRA
Price:
105.29 USD
10.19%
Market Closed
Updated:
May 12, 2024
Section:
Relative Value
The Relative Value of one
NTRA
stock under the Base Case scenario is
90.53
USD.
Compared to the current market price of 105.29 USD,
Natera Inc
is
Overvalued by 14%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
NTRA
Relative Value
Base Case
90.53
USD
Overvaluation 14%
Valuation Multiples
Multiples Across Competitors
NTRA Competitors Multiples
Natera Inc Competitors
Natera Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Natera Inc
NASDAQ:NTRA
|
12.6B USD | 11.6 | -29 | -28.6 | -27.1 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
283.9B USD | 5.2 | 58.9 | 12.8 | 19.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
166.4B USD | 5.6 | 44.2 | 18.6 | 30.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.9B USD | 11 | 30.1 | 24.2 | 25.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.3B USD | 8.2 | 27.8 | 22.5 | 24.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
134.9B AUD | 6.3 | 36 | 21.8 | 27 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
82.2B USD | 3 | 169.8 | 6.8 | 8.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
44.9B USD | 8.7 | -7.5 | -8.1 | -7.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.3B USD | 3.3 | 27.6 | 14.1 | 17.7 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40T KRW | 18.4 | 74.6 | 45.6 | 62.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
